Acumen Pharmaceuticals Announces Journal of Prevention of Alzheimer’s Disease Publication of the Company’s Phase 1 INTERCEPT-AD Study, Including Target Engagement, Dosing Regimen and Safety Findings

Core Viewpoint - The publication of Phase 1 INTERCEPT-AD data supports the continued development of sabirnetug (ACU193) for early Alzheimer's disease treatment, demonstrating its safety, target engagement, and efficacy in reducing amyloid plaques [1][4]. Company Overview - Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing sabirnetug, a humanized monoclonal antibody targeting toxic soluble amyloid beta oligomers (AβOs) for Alzheimer's disease treatment [10]. - The company is headquartered in Newton, Massachusetts, and aims to advance its investigational product candidate through ongoing clinical trials [10]. Clinical Trials - The Phase 1 INTERCEPT-AD trial involved 65 participants with early Alzheimer's disease, showing dose-dependent target engagement and significant amyloid plaque reduction [3][8]. - The ongoing Phase 2 ALTITUDE-AD trial aims to evaluate the efficacy and safety of sabirnetug in approximately 540 adults aged 50 to 90 years, with enrollment expected to complete in the first half of 2025 [6][9]. Drug Mechanism and Development - Sabirnetug is the first humanized monoclonal antibody to demonstrate selective target engagement of AβOs in early symptomatic Alzheimer's disease patients [2]. - The drug targets soluble AβOs, which are believed to be a significant early trigger of neurodegeneration in Alzheimer's disease [7]. Safety and Efficacy Findings - The INTERCEPT-AD trial results indicated a low incidence of amyloid-related imaging abnormalities (ARIA), with only one participant experiencing mild ARIA-E that resolved within four weeks [3][8]. - The study confirmed the safety profile of sabirnetug and established a foundation for the ongoing Phase 2 trial [3][4].